ArticleTranslational oncology2026
Integrated spatial and single‑cell transcriptomics maps disulfidptosis in renal cell carcinoma and reveals PDLIM1 as a prognostic biomarker and potential therapeutic target.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisulfidptosis is a regulated cell death program linked to redox stress, metabolism, and the actin cytoskeleton. Its organization in tissue and clinical relevance in renal cell carcinoma are not well defined.
methodsWe integrated spatial transcriptomics from six renal cancer sections with four single cell RNA sequencing cohorts. Disulfidptosis scores were computed, RCTD deconvolution and epithelial reclustering were used to localize subpopulations, and pathway enrichment and CytoTRACE assessed metabolism and stemness. External validation used TCGA-KIRC, KIRP and additional public datasets. Candidate genes were nominated by intersecting disulfidptosis, Cluster 3, and Epi_C5 signatures. PDLIM1 function was tested by sh-RNA in renal cancer cell lines with qPCR, proliferation, wound healing, and Transwell assays.
resultsDisulfidptosis showed strong intra heterogeneity. Spatial clusters 2, 3, and 6 were enriched, with Cluster 3 higher in tumors and linked to worse survival, and Cluster 6 context dependent yet adverse. Signals localized mainly to epithelial cells. Epithelial reclustering identified Epi_C5 with the highest disulfidptosis and Cluster 3 scores. Disulfidptosis-high cells were enriched for N glycan biosynthesis, purine and pyrimidine metabolism, oxidative phosphorylation, and nitrogen metabolism, with spatial overlap between nitrogen metabolism and disulfidptosis. Epi_C5 upregulated extracellular matrix programs, showed higher CytoTRACE, and associated with poor prognosis in both TCGA cohorts. Intersecting signatures nominated PDLIM1, which was tumor elevated and correlated with Epi_C5 and CytoTRACE. PDLIM1 knockdown reduced proliferation, and migration.
conclusionsWe define a disulfidptosis‑associated epithelial malignant state in renal cancer and nominate PDLIM1 as a candidate node for patient stratification and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.